ライフサイエンスコーパス: N-telopeptide

1 but not cortisol, corticotropin, or urinary N-telopeptide.

2 's reagent, and immunoassay for cross-linked N-telopeptides.

3 with conventional antibiotics, decreases in N-telopeptides (147.3 +/- 77.5 [mean +/- SEM] versus 95.

4 Urine N-telopeptide, a bone resorption marker, levels declined

5 Levels of N-telopeptide, a marker of bone resorption, were greater

6 Serum N-telopeptide, a marker of osteoclast activity, decrease

7 Measurement of serum levels of cross-linked N-telopeptides, a specific measure of bone resorption ac

8 Cross-linked N-telopeptides accounted for two-thirds of the total lys

9 D, parathyroid hormone, osteocalcin, urinary N-telopeptides, albumin, insulin-like growth factor I, a

10 In the upfront group, mean serum N-telopeptide and bone-specific alkaline phosphatase con

11 noline to lysylpyridinoline differed between N-telopeptide and C-telopeptide sites, and between the i

12 0.02, r2 = 0.586, n = 9), and between serum N-telopeptide and total alkaline phosphatase (P < 0.001,

13 Three weeks later, the changes in N-telopeptides and osteocalcin persisted.

14 ne, midtreatment, and posttreatment, urinary N:-telopeptides and serum bone-specific alkaline phospha

15 indirect marker of bone resorption in urine (N:-telopeptide) and 1,25(OH)2D (P < 0.02, r2 = 0.586, n

16 Urinary calcium, N-telopeptide, and pyridinium cross-links were measured

17 Prior studies showed that a docked N-telopeptide can interact with two adjacent collagen mo

18 serum bone alkaline phosphatase, and urinary N-telopeptide collagen crosslink (NTx) concentrations we

19 of change in the bone turnover marker urine N-telopeptide corrected for urine creatinine (uNTx/Cr) f

20 eocalcin and parathyroid hormone and urinary N-telopeptide, cortisol, and calcium excretion were meas

21 phorous increased at 6 months, whereas urine N-telopeptides decreased.

22 he same sites, but concentrated (85%) at the N-telopeptide end.

23 ium intake was significantly correlated with N-telopeptide in the SED group during bed rest weeks 3 a

24 rence, -30%; 95% CI, -26% to -33%) and urine N-telopeptide levels (mean change, -48% vs 4%; between-g

25 y increased BMD and durably suppressed serum N-telopeptide levels for 12 months.

26 Urinary measurements of N-telopeptide (Ntx) and serum bone alkaline phosphatase

27 erminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide t

28 ne formation and resorption, osteocalcin and N-telopeptide (NTX), in patients with AN (n=28) who were

29 hatase and osteocalcin) and bone resorption (N-telopeptide of collagen cross-links); urinalysis; and

30 ly decreased serum levels of osteocalcin and N-telopeptide of collagen cross-links.

31 bone-specific alkaline phosphatase and urine N-telopeptide of collagen.

32 Cross-linked N-telopeptide of type 1 collagen (NTx) breakdown, osteoc

33 Urine was analyzed for cross-linked N-telopeptide of type I collagen, a bone resorption mark

34 nal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell type

35 Markers of bone turnover, N-telopeptides of type 1 collagen, and bone alkaline pho

36 teocalcin, a marker of bone formation; urine N-telopeptides of type I collagen and free deoxypyridino

37 Osteocalcin and N-telopeptides of type I collagen were significantly red

38 alcin, and the ratio of urinary cross-linked N:-telopeptides of type 1 collagen to creatinine with al

39 ed osteocalcin (ucOC) and total osteocalcin, N:-telopeptides of type I collagen (NTx), bone-specific

40 escence alone can underestimate the level of N-telopeptide pyridinoline cross-linking.

41 N-telopeptide pyridinoline fluorescence was quenched on

42 Residue K(160), located in the nonhelical N-telopeptide region and involved in pyridinoline cross-

43 agen, with the binding region located at the N-telopeptide region of type I collagen.

44 cond year, the bone resorption marker, serum N-telopeptide, rose by 27% in the calcitriol group (P< o

45 pyridinoline cross-linking were identified, N-telopeptide to helix and C-telopeptide to helix.

46 Several peptide combinations arose from the N-telopeptide to helix site, but the main source of pyri

47 bisphosphonate use (yes vs no), and urinary N-telopeptide (uNTx) value (<60 mumol/mol creatinine vs

48 Pyridinolines linking two alpha1(N) telopeptides were a minor component.

49 e than 55%, whereas excretion of crosslinked n-telopeptide, which reflects bone resorption, increased